Improving imaging and targeting of HER2 positive esophagogastric cancers using lovastatin
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin
This study is looking at how a cholesterol-lowering drug called lovastatin might help make cancer treatments work better for people with HER2-positive esophagogastric cancers, by understanding a protein that could be blocking these treatments and finding ways to improve their chances of success.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10978233 on NIH RePORTER |
What this research studies
This research investigates how lovastatin, a cholesterol-depleting drug, can enhance the effectiveness of treatments for patients with HER2-positive esophagogastric (EG) cancers. The study focuses on understanding the role of caveolin-1, a protein that may hinder the binding of therapeutic antibodies to cancer cells. By analyzing patient data, the researchers aim to identify biomarkers that can predict treatment outcomes and improve survival rates. The ultimate goal is to develop better therapeutic strategies for patients who currently have limited options due to tumor resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-positive esophagogastric cancers who may benefit from enhanced therapeutic strategies.
Not a fit: Patients with HER2-negative esophagogastric cancers or those who do not express caveolin-1 may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better survival rates for patients with HER2-positive esophagogastric cancers.
How similar studies have performed: Other research has shown promising results in targeting HER2-positive cancers, but the specific approach of using lovastatin in this context is novel.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lewis, Jason S. — Sloan-Kettering Inst Can Research
- Study coordinator: Lewis, Jason S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.